Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Personalized ctDNA detection and genomic profiling in the NeoRHEA Study.

In the NeoRHEA trial of neoadjuvant palbociclib plus endocrine therapy, the RaDaR assay was used to measure ctDNA before treatment, during treatment, and after surgery.

NPJ Breast CancerPubMed 41350280DOI 10.1038/s41523-025-00852-6